A case of an 11-year-old girl diagnosed with OCD developing giggle incontinence following addition of aripiprazole to treatment. Issue 3 (3rd July 2018)

• Record Type: Journal Article
• Authors: Akaltun, İsmail; Kara, Tayfun; Ayaydın, Hamza
• Is Part Of: Psychiatry and clinical psychopharmacology. Volume 28:Issue 3(2018)
• Page Start: 343
• Page End: 345
• Publication Date: 2018-07-03
• Subjects: Giggle incontinence -- aripirazole -- safety -- side effects; Psychopharmacology -- Periodicals; Psychiatry -- Periodicals; Psychiatry; Psychopharmacology; Periodicals; Periodicals; 616
• DOI: 10.1080/24750573.2017.1413724
• Languages: English
• ISSNs: 2475-0573

Abstract

ABSTRACT: Giggle incontinence (GI) is characterized by involuntary and generally unpredictable release of urine during giggling or laughter. It has been suggested that GI may be a centrally mediated disorder and may share a common pathophysiology with narcolepsy and cataplexy. The fact that methylphenidate reduces some symptoms suggests that the condition may be a cataplexy. While alpha 1 and dopamine D2 antagonists exacerbate cataplexy, alpha 1 and dopamine D2 agonists produce a marked improvement. Aripiprazole, frequently used to augment treatment of obsessive compulsive disorder, may have exhibited an alpha 1 and D2 receptor antagonist effect and have caused GI. We describe a case of GI occurring following aripiprazole use in an 11-year-old female obsessive compulsive disorder patient resistant to treatment.